Loading chat...
TX SB2308
Bill
Status
6/11/2025
Primary Sponsor
Tan Parker
Click for details
AI Summary
-
Establishes a framework for creating a consortium to conduct FDA clinical trials for ibogaine as a treatment for opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions where it demonstrates efficacy
-
Requires the consortium to include at least one drug developer, one institution of higher education, and one hospital, with the lead university handling administrative functions and contracting with the Health and Human Services Commission
-
Mandates consortiums must secure matching funds from non-state sources before receiving state funding, and requires quarterly progress and financial reports to the commission with annual reports to the legislature
-
Allocates at least 20% of revenue from intellectual property and commercial rights arising from the clinical trials to the state, with 25% of the state's portion designated for Texas veterans programs
-
Requires physician supervision for ibogaine administration at hospitals or licensed health care facilities once FDA approval is obtained, and directs HHSC to begin accepting consortium proposals within 60 days of the act taking effect
Legislative Description
Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.
State Finances
Last Action
Effective immediately
6/11/2025